Fosamax Osteonecrosis of the Jaw Prognosis: Is Osteonecrosis of the Jaw from Fosamax Permanent?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Risk Awareness

The legacy of general health and science information has long provided a foundational framework for understanding broad physiological principles and common medical conditions. Within this heritage, public awareness campaigns and educational materials have traditionally focused on lifestyle factors, preventive care, and the management of chronic diseases through accessible, non-specialized language. This approach has successfully disseminated knowledge about bone health, dietary guidelines, and the importance of regular medical screenings to diverse populations. However, as scientific inquiry deepens, the scope of health communication must expand to address more specific, context-dependent risks that arise from targeted therapeutic interventions. One such area involves the long-term use of bisphosphonate medications, such as Fosamax, which are prescribed for conditions like osteoporosis. While these drugs have demonstrated efficacy in reducing fracture risk, a growing body of clinical observation has identified a rare but serious adverse event: osteonecrosis of the jaw (ONJ). This condition, characterized by exposed, non-healing bone in the oral cavity, introduces a critical pivot from general health education to a more focused occupational and patient-specific concern. The transition from broad health literacy to this nuanced risk profile requires careful consideration of exposure duration, dosage, and individual susceptibility. For patients and healthcare providers alike, understanding the prognosis of ONJ—whether the condition is permanent or reversible—becomes paramount. This shift in focus underscores the need for targeted communication that bridges general knowledge with specialized, exposure-related outcomes.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is defined as exposed bone in the maxillofacial region that does not heal within eight weeks after identification, occurring in the absence of prior radiation therapy. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Prognosis: Is Osteonecrosis of the Jaw from Fosamax Permanent?

Regarding prognosis, the question of whether ONJ from Fosamax is permanent requires careful consideration of available evidence. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that for many patients, ONJ symptoms may resolve upon discontinuation of Fosamax, but the condition can persist or recur in some individuals. The evidence does not provide a definitive statement that ONJ is universally permanent or reversible; rather, outcomes appear variable. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), indicating that cessation of the drug is a management strategy that can influence prognosis. The mechanistic pathways linking Fosamax to ONJ involve the drug's action on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can lead to suppressed bone turnover. The jawbone has unique characteristics that may make it particularly susceptible to such suppression. Current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores that the jawbone's distinct biology may contribute to the development and persistence of ONJ. However, the evidence does not establish a direct timeline from exposure to documented harm beyond noting that onset can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Risk anchors related to the adequacy of warnings indicate that the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4), which describes the condition, associated risk factors, and management considerations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warnings note that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may influence risk perception. Prognosis-related considerations for affected patients include the potential for symptom relief after discontinuation, but also the possibility of recurrence upon rechallenge. The timeline between exposure and documented harm is variable, with symptoms appearing as early as one day or as late as several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients at low risk for fracture, the prescribing information suggests considering drug discontinuation after 3 to 5 years of use, as the optimal duration of use has not been determined (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This recommendation may indirectly affect ONJ risk by limiting cumulative exposure. In summary, the prognosis for ONJ from Fosamax is not uniformly permanent. Most patients experience relief of symptoms after stopping the drug, but a subset may have persistent or recurrent issues. The condition is associated with known risk factors, and management strategies such as drug discontinuation before invasive dental procedures may improve outcomes. The evidence does not support a definitive conclusion that ONJ is always permanent, but it does highlight variability in patient outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed bone in the maxillofacial region that does not heal within eight weeks, occurring in the absence of prior radiation therapy. It is a known adverse effect associated with bisphosphonate use, including Fosamax (alendronate). ONJ can occur spontaneously but is often associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Is osteonecrosis of the jaw from Fosamax permanent?

The prognosis for ONJ from Fosamax is not uniformly permanent. Most patients experience relief of symptoms after stopping the drug, though a subset may have persistent or recurrent issues. The evidence shows that symptoms can resolve upon discontinuation, but recurrence is possible if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Management strategies, such as drug discontinuation before invasive dental procedures, may improve outcomes.

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.